Tim Greten
Tim Greten
National Cancer Institute
Verified email at nih.gov - Homepage
Cited by
Cited by
Sorafenib in advanced hepatocellular carcinoma
JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer
FR Greten, L Eckmann, TF Greten, JM Park, ZW Li, LJ Egan, MF Kagnoff, ...
Cell 118 (3), 285-296, 2004
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study
J Lammer, K Malagari, T Vogl, F Pilleul, A Denys, A Watkinson, M Pitton, ...
Cardiovascular and interventional radiology 33 (1), 41-52, 2010
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
V Bronte, S Brandau, SH Chen, MP Colombo, AB Frey, TF Greten, ...
Nature communications 7 (1), 1-10, 2016
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells
B Hoechst, LA Ormandy, M Ballmaier, F Lehner, C Krüger, MP Manns, ...
Gastroenterology 135 (1), 234-243, 2008
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
LA Ormandy, T Hillemann, H Wedemeyer, MP Manns, TF Greten, ...
Cancer research 65 (6), 2457-2464, 2005
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma
EOF Research, TO Cancer, ...
Journal of hepatology 56 (4), 908-943, 2012
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
B Hoechst, T Voigtlaender, L Ormandy, J Gamrekelashvili, F Zhao, ...
Hepatology 50 (3), 799-807, 2009
Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer
DT Le, A Wang-Gillam, V Picozzi, TF Greten, T Crocenzi, G Springett, ...
Journal of clinical oncology 33 (12), 1325, 2015
Myeloid derived suppressor cells in human diseases
TF Greten, MP Manns, F Korangy
International immunopharmacology 11 (7), 802-807, 2011
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
C Ma, M Han, B Heinrich, Q Fu, Q Zhang, M Sandhu, D Agdashian, ...
Science 360 (6391), 2018
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
AG Duffy, SV Ulahannan, O Makorova-Rusher, O Rahma, H Wedemeyer, ...
Journal of hepatology 66 (3), 545-551, 2017
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial
H Oettle, H Riess, JM Stieler, G Heil, I Schwaner, J Seraphin, M Görner, ...
Journal of clinical oncology 32 (23), 2423-2429, 2014
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
C Ma, AH Kesarwala, T Eggert, J Medina-Echeverz, DE Kleiner, P Jin, ...
Nature 531 (7593), 253-257, 2016
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway
LA Haile, R Von Wasielewski, J Gamrekelashvili, C Krüger, O Bachmann, ...
Gastroenterology 135 (3), 871-881. e5, 2008
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
D Malka, P Cervera, S Foulon, T Trarbach, C de la Fouchardière, ...
The lancet oncology 15 (8), 819-828, 2014
Direct visualization of antigen-specific T cells: HTLV-1 Tax11–19-specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP …
TF Greten, JE Slansky, R Kubota, SS Soldan, EM Jaffee, TP Leist, ...
Proceedings of the National Academy of Sciences 95 (13), 7568-7573, 1998
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo
SR Scheffer, H Nave, F Korangy, K Schlote, R Pabst, EM Jaffee, ...
International journal of cancer 103 (2), 205-211, 2003
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients
TF Greten, F Papendorf, JS Bleck, T Kirchhoff, T Wohlberedt, S Kubicka, ...
British journal of cancer 92 (10), 1862-1868, 2005
The system can't perform the operation now. Try again later.
Articles 1–20